Menu

Blog

Jan 7, 2023

MRNA cancer therapies planned for 2030

Posted by in categories: biotech/medical, government

BioNTech has announced a strategic partnership with the UK government to provide up to 10,000 patients with personalised mRNA cancer immunotherapies by 2030.

BioNTech is famous for having partnered with Pfizer to develop a COVID-19 vaccine, based on messenger RNA (mRNA). More recently, the company has been further developing this technology to investigate its potential in treating other diseases, such as cancer. One study, which involved the injection of mRNA into colon and melanoma tumours in mice, halted tumour growth and caused a complete regression of cancer in 85% of the animals. A phase 1 trial in 231 humans is currently underway and expected to conclude in 2024.

Comments are closed.